News | Heart Valve Technology | January 11, 2018

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System

System recalled for mold overflow defect that may embolize and obstruct blood flow

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System

January 11, 2018 — The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery System due to a molding overflow defect in the button valve within the loader. The overflow material could detach during placement of the delivery system and potentially embolize into the patient, according to the FDA. Such an embolism could obstruct blood flow to critical organs, leading to serious injury and/or a need to surgically extract the overflow material from the patient. In dire situations, severe neurologic, cardiac, limb, renal or gastrointestinal injury may result.

The recall encompasses select lot numbers between 60677270 and 60990824, with manufacturing dates between Nov. 22, 2016 to July 10, 2017, and distribution dates between Jan. 9, 2017 to July 17, 2017.

On July 21, 2017, Edwards LifeSciences sent affected customers a "Recall Notification Letter" informing them of the device's risks. In the letter, Edwards LifeSciences directed customers to:

  • Complete the "Acknowledgement Form" that accompanied the Recall Notification Letter.
  • Check all inventory for affected models of the Certitude Delivery System.
  • Return the "Acknowledgement Form" and all affected models of the Certitude Delivery System to Edwards LifeSciences as indicated in the Recall Notification Letter.

The Edwards LifeSciences Certitude Delivery System is used for delivery of the Edwards Sapien 3 transcatheter heart valve (THV), typically used during a transcatheter aortic valve replacement (TAVR).

The system includes a balloon catheter that expands a compressed (crimped) THV, a loader that delivers the THV through the guiding tube and extension tubing. During a procedure, the physician will first crimp the THV onto the balloon of the Certitude Delivery System. The system is then inserted into the body, usually during a transapical (inserted through small incision under left breast) or transaortic (inserted through small incision in the top right side of the chest) approach. The THV is then deployed through the guiding tube to the site of the native stenotic aortic valve, where it is expanded and fixed in place.

Customers with questions regarding this recall may contact Edwards Customer Service at 1-800-424-3278, from 6:00 AM to 4:30 PM (Pacific Time).

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information: www.fda.gov

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init